Human ErbB2 ELISA kit
- Known as:
- Human ErbB2 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- BEK1052
- Product Quantity:
- 96 T
- Category:
- Elisa Kits
- Supplier:
- Biospect
- Gene target:
- Human ErbB2 ELISA kit
Related genes to: Human ErbB2 ELISA kit
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: Human ErbB2 ELISA kit
Related articles to: Human ErbB2 ELISA kit
- Despite recent advances, long-term survival in metastatic carcinomas such as ovarian cancer remains limited by off-tumour toxicities of targeted therapies and low response rates to immunotherapy. Synthetic proteins have been engineered for selective recognition of oncogenic signalling states, but how they can be used to treat metastatic disease in vivo remains unclear. Addressing cancers driven by ErbB-family receptor tyrosine kinases such as EGFR and HER2, we used engineered proteins to restrict replication of a clinically approved viral backbone to kill cells with aberrant ErbB signalling. The resulting ErbB oncogene-selective virus (ErbB-OSV) showed superior safety to a benchmark oncolytic virus of the same family and superior efficacy against ErbB2/HER2-positive ovarian cancer xenografts. In a syngeneic model of advanced ovarian cancer, combining ErbB-OSV with chemotherapy and enabling repeated dosing by B cell depletion conferred a 180% larger survival benefit compared to chemotherapy alone, while single-agent ErbB-OSV cured most early cases. Thus, rationally restricting viral replication to ErbB-hyperactive cells with synthetic signalling proteins yields a highly specific therapeutic agent that ablates metastatic tumours in vivo more effectively than existing treatments. - Source: PubMed
Publication date: 2026/06/12
Zou XinzhiPalafox ElizabethZhao CynthiaBeier Kevin TKang Chil-YongLin Michael Z - Dabrafenib plus trametinib is a standard first-line treatment for V600E-mutated non-small cell lung cancer (NSCLC). The LiBRA study aimed to explore the role of liquid biopsy in detecting and monitoring V600E mutation, assessing its potential to predict treatment response and emerging resistance. - Source: PubMed
Publication date: 2026/06/12
Leonetti AlessandroPluchino MonicaMinari RobertaPassiglia FrancescoPizzutilo Elio GregoryCortinovis Diego LuigiToschi LucaGelsomino FrancescoFrega StefanoMetro GiulioBelluomini LorenzoMontrone MicheleCamerini AndreaBertolini AlessandroBaldini EdittaMazzoni FrancescaBria EmilioBertolini FedericaDel Conte AlessandroBordi PaolaPerrone FabianaVerzè MichelaD'Agnelli SimonaOnorini PaolaCosenza AgneseFacchinetti FrancescoBoni LucaTognetto MicheleTiseo Marcello - This review discusses the role of human epidermal growth factor receptor 2 (HER2/) as a key oncogenic driver in non-small cell lung cancer (NSCLC), including exon 20 activating mutations, gene amplification, and protein overexpression. These forms differ in their biological effects and predictive value, but HER2 mutations, especially exon 20 insertions, are the primary oncogenic mechanism. Regarding diagnosis, Next-Generation Sequencing (NGS) is used to identify mutations, whereas Immunohistochemistry (IHC) and in situ hybridization are used to assess HER2 expression. Concerning treatment, in advanced HER2-positive, Non-Squamous NSCLC tumors, the first-line treatment is Platinum-based + Pemetrexed chemotherapy, with or without immunotherapy, because no HER2-targeted antibody therapy has yet been approved for initial treatment. After progression, HER2-targeted antibody-drug conjugates like Trastuzumab-Deruxtecan and Ado Trastuzumab-Emtansine may offer patients clinical benefits. New HER2-selective tyrosine kinase inhibitors, such as zongertinib and sevabertinib, have shown promising results, including patients previously treated with antibody-drug conjugates (ADCs). Recent advances, including next-generation ADCs such as SHR-A1811 and A166, and bispecific antibodies, such as zenocutuzumab for NRG1 fusion-positive disease, which are also expanding treatment options. Overall, advances in diagnostics and new targeted therapies are changing how HER2-altered NSCLC is treated and are helping to make care more personalized. - Source: PubMed
Publication date: 2026/05/29
Richani Meinhardt Fedor WadiZambrano Iglesias Mijail IFernández Gómez María PSaltaren Fonseca Jesús FHussein AtifRaez Luis E - Human epidermal growth factor receptor 2 (HER2) dysregulation contributes to tumorigenesis in gastric and gastroesophageal junction adenocarcinomas (GC/GEJ). HER2 overexpression has been associated in multiple cohorts with aggressive behavior and poor outcomes. While HER2 amplification has long guided therapy in HER2-positive disease, antibody-drug conjugates (ADCs) have shifted attention toward the HER2-low category, typically defined as immunohistochemistry (IHC) 1+ or IHC 2+ with negative in situ hybridization (ISH). This narrative review integrates evidence from the peer-reviewed literature, current testing recommendations, and registered clinical trials. It clarifies practical issues in HER2-low assessment and maps the evolving therapeutic landscape of HER2-targeted ADCs including rational combination strategies that may extend benefit beyond conventionally HER2-positive tumors. A cross-tumor perspective contrasts GC/GEJ testing and biology with the breast cancer paradigm and summarizes the importance of HER2-low expression in non-gastric malignancies. Finally, we discuss the therapeutic strategies in HER2-low GC/GEJ and highlight key safety and monitoring considerations for HER2-directed ADCs. - Source: PubMed
Publication date: 2026/05/22
Scurtu Alexandra GeorgianaSala Daniela TatianaJung IoanBara TivadarNeagoe Radu MirceaFülöp Zsolt ZoltánGurzu Simona - Assessment of HER2 overexpression and gene (ERBB2) amplification remains an essential predictive test that determines tailored breast cancer therapy. Based on institutional needs, we recently validated the VENTANA HER2 Dual ISH DNA Probe Cocktail assay (DISH). Validation included testing 61 retrospective breast cancers, followed by 40 prospective cases (parallel testing). There was 99% concordance for binary positive/negative status when correlated with immunohistochemistry, and 87% concordance for exact ISH category (groups 1 to 5). We designed an online tool for automatic calculation of ratios and group assignment, with prompts for additional counting when needed. During the first year, 1286 DISH assays were performed, with 2.9% initial assay failures requiring repeat. Based on conservative guidelines in the first year, we sent confirmatory fluorescence in situ hybridization (FISH) in 4% of cases; 9 cases (0.7%) had discordant DISH and FISH results, all of which were near a threshold (including "low amplified" results with HER2/CEP17 ≥2, average HER2/cell 4 to 6). The average turnaround time for HER2 DISH from ordering to finalization was 3.0 days, versus 4.8 days for FISH at our institution (37.5% improvement). We encountered occasional pitfalls, including zones lacking hybridization signals, and enhanced silver dust associated with anthracosis or tattoo pigment. We also observed differences across whole slide scanner platforms. HER2 DISH advantages included the ability of pathologists to directly score slides in correlation with morphology and immunohistochemistry, improved turnaround time, and greater automation for high-volume HER2 testing, as compared with FISH. In summary, we found HER2 DISH to be an accurate and practical alternative. - Source: PubMed
Publication date: 2026/06/10
Troxell Megan LDussaq Alex MSolarewicz JoannaSalisbury TaylorYoung KellyHsu NancyHammer PhoebeKarakas CansuOllila EricZhang XiaomingLam Maggie MErnst KellyWest Robert BAllison Kimberly HBean Gregory R